english
français
RP2E INRA Université de Lorraine

Publications

Use of active salmon-lecithin nanoliposomes to increase polyunsaturated fatty acid bioavailability in cortical neurons and mice

International Journal of Molecular Sciences, 22 (21), pp. 11859.

Passeri, E., Elkhoury, K., Jimenez Garavito, M.C., Desor, F., Huguet-Cizo, M., Soligot-Hognon, C., Linder, M., Malaplate, C., Yen, F.T., Arab-Tehrany, E.

2021

Omega-3 polyunsaturated fatty acids (n-3 PUFAs) play an important role in the development,
maintenance, and function of the brain. Dietary supplementation of n-3 PUFAs in neurological
diseases has been a subject of particular interest in preventing cognitive deficits, and particularly
in age-related neurodegeneration. Developing strategies for the efficient delivery of these lipids
to the brain has presented a challenge in recent years. We recently reported the preparation of n-3
PUFA-rich nanoliposomes (NLs) from salmon lecithin, and demonstrated their neurotrophic effects
in rat embryo cortical neurons. The objective of this study was to assess the ability of these NLs
to deliver PUFAs in cellulo and in vivo (in mice). NLs were prepared using salmon lecithin rich in
n-3 PUFAs (29.13%), and characterized with an average size of 107.90 0.35 nm, a polydispersity
index of 0.25+/- 0.01, and a negative particle-surface electrical charge (-50.4+/- 0.2 mV). Incubation of
rat embryo cortical neurons with NLs led to a significant increase in docosahexaenoic acid (DHA)
(51.5%, p < 0.01), as well as palmitic acid, and a small decrease in oleic acid after 72 h (12.2%, p < 0.05).
Twenty mice on a standard diet received oral administration of NLs (12 mg/mouse/day; 5 days
per week) for 8 weeks. Fatty acid profiles obtained via gas chromatography revealed significant
increases in cortical levels of saturated, monounsaturated, and n-3 (docosahexaenoic acid,) and n-6
(docosapentaenoic acid and arachidonic acid) PUFAs. This was not the case for the hippocampus
or in the liver. There were no effects on plasma lipid levels, and daily monitoring confirmed NL
biocompatibility. These results demonstrate that NLs can be used for delivery of PUFAs to the brain.
This study opens new research possibilities in the development of preventive as well as therapeutic
strategies for age-related neurodegeneration.

Imprimer le document

Voir le document sur le site de l'éditeur

178 Publications depuis 2019

Imprimer le listing

2024

ACL - Articles comité de lecture référencés bases de données HCÉRES

2023

ACL - Articles comité de lecture référencés bases de données HCÉRES

2022

ACL - Articles comité de lecture référencés bases de données HCÉRES

2021

ACL - Articles comité de lecture référencés bases de données HCÉRES

ACLN - Articles comité de lecture non-référencés bases de données HCÉRES

2020

ACL - Articles comité de lecture référencés bases de données HCÉRES

ACLN - Articles comité de lecture non-référencés bases de données HCÉRES

2019

ACL - Articles comité de lecture référencés bases de données HCÉRES

ACLN - Articles comité de lecture non-référencés bases de données HCÉRES

Voir les productions antérieures

Toutes les productions scientifiques